The First Food and Drug Administration-Indicated Drug for Postpartum Depression-Brexanolone

JAMA Psychiatry. 2019 Oct 1;76(10):1001-1002. doi: 10.1001/jamapsychiatry.2019.1546.

Authors

Katherine L Wisner^{1

2}, Catherine S Stika², Jody D Ciolino³

Affiliations

¹ Asher Center for the Study and Treatment of Depressive Disorders, Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
³ Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

PMID: 31241747
DOI: 10.1001/jamapsychiatry.2019.1546

No abstract available

Publication types

Comment

MeSH terms

Depression, Postpartum* / drug therapy
Double-Blind Method
Drug Combinations
Female
Humans
Pregnanolone
United States
United States Food and Drug Administration
beta-Cyclodextrins

Substances

Drug Combinations
beta-Cyclodextrins
brexanolone
Pregnanolone